Research into a potential new drug treatment for treatment-resistant depression is being carried out in Oxford.
The Oxford Health Clinical Research Facility recently launched the COMP006 study, which focuses on the efficacy, safety and tolerability of potential treatments.
Treatment-resistant depression is a condition that affects many people and does not respond to at least two types of antidepressants.
This international study will test various doses of the investigational COMP360 psilocybin treatment.
Psilocybin, a psychedelic substance, acts on the serotonin system in the brain, which is involved in regulating mood, sleep, and thought processes.
COMP360 is a synthetically produced psilocybin formulation that is administered with psychological support from a trained therapist during the trial.
The study’s principal investigator, Dr. Katherine Smith, and her team are looking for patients with treatment-resistant depression who meet specific eligibility criteria to participate in the study, which includes a 52-week follow-up period.
She said: “We are excited to begin the COMP006 study at the Oxford Health Clinical Research Facility.
“Treatment-resistant depression has a significant impact on people’s lives, and this study may provide a new and different approach.
“This study helps show whether new investigational treatments are effective and, if so, how long their effects last.”
If you live within an 80 mile radius of Oxford and would like more information, please email mentalhealthresearch@oxfordhealth.nhs.uk.
